Columbia Technology Ventures

Mouse line as a model for Peripheral T-cell Lymphoma with GATA3+ features

This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells.

Unmet Need: In vitro and in vivo models for Peripheral T-cell Lymphoma

Peripheral T-cell Lymphomas (PTCLs) represent a heterogeneous and poorly understood pathological group of non-Hodgkin lymphomas associated with poor prognosis, particularly in those with the GATA3+ subtype. Mutations in the Vav1-Myof1 fusion oncogene can result in PTCL. Animal models are necessary to better understand the role of Vav1-Myof1 and develop targeted treatments for these disorders. However, there are currently few animal models to study PTCL in vivo, and none that look specifically at this oncogene.

The Technology: Conditional knock-in cell and mouse models for Peripheral T-cell Lymphoma

This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells. It can be used to study PTCL with GATA3+ features and screen targeted treatments. It can also be used to understand the role of Vav1-Myof1 in hematological malignancies and screen potential therapeutics.

Applications:

  • Therapeutic screening for PTCL
  • Research tool for analysis of tumor microenvironment
  • Research tool for analysis of tumor-suppressing agents
  • Research tool for analysis of Peripheral T-cell lymphoma pathogenesis
  • Diagnostic assays for cancers
  • Genetic screening of cancerous mutations

Advantages:

  • Replicates human diseases associated with Vav1-Myof1
  • Creates consistent and reproducible genetic knockouts
  • Knocks out Vav1-Myof1 only in specific cells of interest
  • Provides a model of Peripheral T-cell Lymphoma with GATA3+ features
  • High-throughput platform for disease analysis and drug screening

Lead Inventor:

Teresa Palomero, Ph.D.

Related Publications:

Tech Ventures Reference: